Orthofix International NV  

(Public, NASDAQ:OFIX)   Watch this stock  
Find more results for ofix
26.52
-0.34 (-1.27%)
May 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 26.40 - 26.80
52 week 25.30 - 45.62
Open 26.80
Vol / Avg. 182,544.00/258,367.00
Mkt cap 515.90M
P/E 11.09
Div/yield     -
EPS 2.39
Shares 19.45M
Beta 1.04
Inst. own 92%
Jul 22, 2013
Q2 2013 Orthofix International Earnings Release Add to calendar
Jun 20, 2013
Orthofix International Annual Shareholder Meeting - 10:00AM EDT - Add to calendar
May 8, 2013
Q1 2013 Orthofix International Earnings Conference Call
May 8, 2013
Q1 2013 Orthofix International Earnings Release
Mar 19, 2013
Orthofix International at Canaccord Genuity Musculoskeletal Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 4.90% 11.67%
Operating margin 8.41% 19.25%
EBITD margin - 24.06%
Return on average assets 3.91% 8.99%
Return on average equity 4.91% 15.10%
Employees 892 -
Carbon Disclosure Rating - -

Address

7 Abraham de Veerstraat
CURACAO,
Curacao
+599-9-4658525 (Phone)
+599-9-4616978 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Orthofix International N.V. (Orthofix) is a diversified, global medical device company focused on developing and delivering repair and regenerative solutions to the spine and orthopedic markets. The Company operates in two global business units, which include Spine and Orthopedics. It designs, develops, manufactures, markets and distributes medical equipment used principally by musculoskeletal medical specialists for spine and orthopedic applications. Its main products are spinal implant products and related human cellular and tissue based products (HCT/P products) used in surgical procedures, non-invasive regenerative stimulation products used to enhance bone growth and the success rate of spinal fusions and to treat non-union fractures, external and internal fixation devices used in fracture repair, limb lengthening and bone reconstruction.

Officers and directors

James F. Gero Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Bradley R. Mason President, Chief Executive Officer
Bio & Compensation  - Reuters
Emily V. Buxton Chief Financial Officer
Age: 36
Bio & Compensation  - Reuters
Brian McCollum President - Spine Global Business Unit
Age: 37
Bio & Compensation  - Reuters
Jeffrey M. Schumm Senior Vice President, General Counsel, Corporate Secretary
Age: 51
Bio & Compensation  - Reuters
Michael M. Finegan Senior Vice President - Corporate Development; President - Biologics
Age: 49
Bio & Compensation  - Reuters
Maria Degois Sainz Director
Age: 47
Bio & Compensation  - Reuters
Davey S. Scoon CPA Independent Director
Age: 66
Bio & Compensation  - Reuters
Guy J. Jordan Ph.D. Non-Executive Independent Director
Age: 63
Bio & Compensation  - Reuters
Michael R. Mainelli Jr. Non-Executive Independent Director
Age: 50
Bio & Compensation  - Reuters